Why us? Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

Author Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making.

MD MRCGP DFFP
Was this answer helpful?
Authored and medically reviewed by Dr Farzana Khan on 19 August 2026
Rate Dr Farzana's explanation
Polynucleotides via automated multi-injection for refractory dryness | WHC Clinical FAQ

Polynucleotides via automated multi-injection for refractory dryness | WHC Clinical FAQ

Polynucleotides via automated multi-injection for refractory dryness | WHC Clinical FAQ

Polynucleotides via automated multi-injection for refractory dryness | WHC Clinical FAQ

What are intimate polynucleotides made from? | WHC Clinical FAQ

What are intimate polynucleotides made from? | WHC Clinical FAQ

Are polynucleotides a safe alternative to HRT? | WHC Clinical FAQ

Are polynucleotides a safe alternative to HRT? | WHC Clinical FAQ




Quality control


Source material


Traceability

Women’s Health Clinic FAQ

What USP and European Pharmacopoeia quality standards govern the extraction and sterility verification of medical-grade polynucleotides

Source and purification questions are central to polynucleotide safety because fish-derived DNA claims need documentation, not reassurance by label alone.

Direct answer

USP and European Pharmacopoeia references should be discussed as quality-standard context, not as invented product approval. The answer should focus on sterility, endotoxin, microbiological testing, source traceability and documentation. For patients, the key point is to ask about source, sterility, traceability and allergy context rather than trusting labels alone. Suitability and safety should be confirmed in consultation, especially where symptoms involve pain, bleeding, infection signs, fish allergy concerns, active vulvar disease or severe atrophy.

This page translates cellular and material-science claims into cautious patient information, with mechanism, evidence and suitability kept separate.


Educational only. This is general education about intimate polynucleotide science and does not replace individual clinical assessment. Results vary. Not a cure.

Educational WHC FAQ image for What USP and European Pharmacopoeia quality standards govern the extraction and sterility verification of medical-grade polynucleotides

Polynucleotide evidence review

At a glance

These quick points help separate laboratory mechanism, product quality and patient outcome.

Key context

What the science can and cannot tell us.

Source matters

Salmon-derived DNA should be discussed with traceability and allergy context.

Purity needs evidence

Protein removal, sterility and contaminants should be documented.

Standards are context

USP or European Pharmacopoeia language does not automatically prove intimate-use benefit.

Lab tests have limits

Biocompatibility and cell-viability assays do not equal patient outcomes.

Important evidence note

PN/PDRN mechanisms should not be translated into promised intimate-health outcomes without product-specific documentation and clinical evidence.

Source
Sterility
Allergy
Batch
Testing




Detailed answer

Detailed answer

The useful answer starts with the underlying biology, then explains how evidence quality, product testing and patient context change interpretation.

Clinical bottom line

Polynucleotide science can be biologically plausible and still not prove a predictable patient result. That distinction is central to safe consent.

Mechanism
Quality
Evidence
Consent

Explain documentation

Patients can ask how source, batch, sterility, endotoxin and contaminant checks are recorded.

Avoid manufacturing detail

Public content should explain why purification matters without listing processing steps or settings.

Discuss allergy carefully

Fish or seafood allergy history should be reviewed rather than dismissed because a product is purified.

Separate quality and efficacy

A well-documented product still needs evidence for the specific intimate-health claim.

How to interpret this safely

A responsible discussion should ask whether the claim is based on material behaviour, laboratory mechanism, product tests or patient outcome data.

If the topic relates to intimate symptoms, GSM, scarring, inflammation, allergy or pelvic pain, the symptom still needs clinical assessment before treatment suitability is discussed.





Patient safety

Why this matters

Polynucleotide language sits between material science, cellular repair biology and patient care, so accuracy protects consent and expectations.

It protects consent

Patients should know whether a claim is proven clinically, inferred from mechanism or still uncertain.

It protects safety

Source material, sterility, traceability and allergy history matter for fish-derived DNA products.

It protects expectations

Regenerative wording can sound more certain than the evidence supports, especially for intimate-health outcomes.

It protects diagnosis

Dryness, pain, bleeding, fissures or inflammatory symptoms should not be bypassed by a treatment label.

The safer interpretation

Polynucleotides may be discussed as hydrating and signalling materials with possible biological effects, not as a promised repair system.

The stronger the claim, the more important it is to ask for product-specific evidence, documentation and a clear clinical reason.





Considerations

What to consider before treatment

Before considering intimate polynucleotide treatment, the discussion should separate symptom assessment, product documentation, evidence quality and realistic alternatives.

When caution should increase

Be especially cautious with pregnancy, active infection, unexplained bleeding, fish allergy concerns, active LS, severe atrophy, immune conditions or unclear product documentation.

Source
Sterility
Allergy
Batch

The symptom

Clarify whether the concern is dryness, pain, scarring, irritation, tissue fragility, sexual discomfort or a technical product question.

The evidence

Ask whether evidence is clinical, laboratory-based, product-specific or extrapolated from another tissue or condition.

The product

Source, purification, sterility, endotoxin, microbiological safety and traceability should be documented.

The alternatives

Standard GSM care, moisturisers, lubricants, pelvic-floor care, dermatology review or specialist assessment may be more appropriate in some cases.

Practical expectations

A consultation should explain uncertainty plainly, including what is known about the mechanism and what is not yet established for patient outcomes.

Public pages should not provide dosing, procedural depth, product-preparation, sterile-processing or treatment-planning instructions.





Common concerns and myths

Common misconceptions

These myths are common when laboratory science is translated too quickly into clinical marketing.

Myth: Salmon-derived DNA is automatically allergy-free

Reality: the concept is more nuanced and needs evidence, documentation and clinical context before it can guide patient decisions.

Myth: Medical-grade means clinically proven for intimate use

Reality: one measurement or pathway rarely proves product quality, tissue response or patient benefit on its own.

Myth: Sterility language replaces transparent documentation

Reality: responsible care separates plausible mechanism from proven outcome and keeps suitability assessment central.

Mechanism versus outcome

A pathway can be biologically plausible without proving a specific improvement in dryness, tissue quality, comfort or sexual function.

Documentation versus marketing

Quality claims should be backed by clear documentation rather than vague terms or product-ranking language.





Safety checklist

Safety checklist

Use these checks before assuming a polynucleotide-based option is appropriate.

Has the symptom been assessed?

Dryness, pain, bleeding, fissures and inflammatory symptoms can have different causes and may need standard medical care first.

Is the evidence clear?

Ask whether claims are based on patient outcomes, laboratory studies, product tests or extrapolation.

Is documentation available?

Source, purification, sterility, endotoxin, microbiological safety and traceability should be explainable.

Are expectations realistic?

Treatment should not be framed as certain tissue repair, a substitute for HRT, or a promised sexual or urinary outcome.

Reassuring signs

The plan is more reassuring when symptoms are assessed, documentation is clear, alternatives are discussed and uncertainty is explained.

Assessed
Documented
Cautious

Reasons to pause

Seek medical advice promptly for severe or worsening pelvic pain, heavy or unexplained bleeding, fever, offensive discharge, sudden swelling, ulcers, allergic symptoms or feeling very unwell.

Pain
Bleeding
Infection




When to escalate

When to seek medical help

Some intimate symptoms need medical review rather than treatment shopping or waiting for a regenerative option.

Use NHS 111 online

Severe or worsening symptoms

Severe pelvic or vulval pain, rapid swelling, heavy bleeding or feeling faint should be assessed urgently.

Infection symptoms

Fever, offensive discharge, ulcers, worsening burning, pelvic pain or feeling very unwell needs prompt review.

Complex history

Fish allergy concerns, active LS, pelvic radiation, immune suppression, scarring or persistent pain should lower the threshold for specialist advice.

Emergency symptoms

Call 999 in a life-threatening emergency, including collapse, chest pain, breathing difficulty or sudden neurological symptoms.

Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.

More clinical detail

Why quality language can mislead

Terms such as purified, medical grade or biocompatible sound reassuring, but patients need to know what has actually been tested and what the result proves.

What transparent consent includes

Consent should cover source, documentation, evidence limits, alternatives, allergy history and why suitability cannot be confirmed from marketing language.

Next step

Book an intimate health consultation

A consultation can clarify whether symptoms need standard GSM care, pelvic assessment, dermatology review, product-documentation checks or a careful discussion about evidence-limited regenerative options.

View Research Sources (12 Sources)
• NICE menopause guideline
• NICE shared decision making
• NHS vaginal dryness
• EANM guideline on the validation of analytical methods for radiopharmaceuticals - PMC
• PubMed - PDRN purification deproteinisation salmon DNA
• PubMed PDRN adenosine A2A receptor inflammation
• PubMed polydeoxyribonucleotide tissue repair extracellular matrix
• Effect of Polydeoxyribonucleotide on Angiogenesis and Wound Healing in an In Vitro Model of Osteoarthritis - PMC
• Polydeoxyribonucleotide (PDRN) in Dentistry: Narrative Review for Mechanisms and Emerging Clinical Applications - PMC
• MHRA good manufacturing practice and distribution guidance
• European Pharmacopoeia
• USP standards

These 12 source names are selected from 120 curated sources. Additional reviewed material included peer-reviewed clinical papers; duplicate and low-relevance records were removed before display.

Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.

  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.